Drugs Made In America Acquisition Corp. $DMAA Shares Acquired by Clear Street Group Inc.

Clear Street Group Inc. raised its holdings in shares of Drugs Made In America Acquisition Corp. (NASDAQ:DMAA) by 55.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 325,973 shares of the company’s stock after purchasing an additional 116,407 shares during the period. Clear Street Group Inc.’s holdings in Drugs Made In America Acquisition were worth $3,382,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Sandia Investment Management LP acquired a new position in shares of Drugs Made In America Acquisition during the third quarter worth $161,000. Quarry LP acquired a new position in shares of Drugs Made In America Acquisition during the third quarter worth $161,000. JPMorgan Chase & Co. acquired a new position in shares of Drugs Made In America Acquisition during the third quarter worth $1,024,000. Shaolin Capital Management LLC acquired a new position in shares of Drugs Made In America Acquisition during the second quarter worth $1,020,000. Finally, Radcliffe Capital Management L.P. acquired a new position in shares of Drugs Made In America Acquisition during the second quarter worth $1,293,000.

Drugs Made In America Acquisition Price Performance

NASDAQ DMAA opened at $10.61 on Friday. The stock’s fifty day moving average price is $10.57 and its 200 day moving average price is $10.47. Drugs Made In America Acquisition Corp. has a 1 year low of $10.17 and a 1 year high of $10.62.

Drugs Made In America Acquisition (NASDAQ:DMAA) last released its earnings results on Thursday, May 14th. The company reported $0.06 earnings per share (EPS) for the quarter.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Drugs Made In America Acquisition in a research report on Friday, May 29th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock currently has an average rating of “Sell”.

About Drugs Made In America Acquisition

Drugs Made In America Acquisition Corp (NASDAQ: DMAA) is a special purpose acquisition company incorporated in Delaware with the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The company’s stated focus is on identifying and acquiring one or more operating businesses in the U.S. pharmaceutical sector, particularly those involved in the domestic manufacturing of approved drugs, active pharmaceutical ingredients or related contract development and manufacturing services.

Operating as a blank?check vehicle, Drugs Made In America Acquisition holds its funds in a trust account pending the completion of an initial business combination.